Pfizer and Bristol-Myers Squibb report positive trial data for Eliquis antidote

Pfizer and Bristol-Myers Squibb have announced positive clinical trial data for a new therapy designed to reverse the effects of their anticoagulant Eliquis.

Working in collaboration with Portola Pharmaceuticals, the companies have reported statistically significant results from the first part of the phase III Annexa-A studies, which assessed investigational andexanet alfa with Eliquis.

It was found that andexanet alfa produced rapid and nearly complete reversal, by approximately 94 percent, of the anticoagulant effect of Eliquis in healthy volunteers between the ages of 50 and 75.

This means the new product was able to meet all of its primary and secondary endpoints with statistical significance in the study.

Dr Steven Romano, senior vice-president and head of the medicines development group within Pfizer's global innovative pharmaceutical business, said: "Bristol-Myers Squibb and Pfizer's collaboration with Portola for the development and evaluation of andexanet alfa with Eliquis further demonstrates our commitment to delivering innovative therapies."

Eliquis is approved for a number of indications, including in the treatment of atrial fibrillation, deep vein thrombosis and pulmonary embolism. For clinical reasons, it may sometimes be necessary to reverse its effects, hence this new study.